CCL5 and neoplasm: Based on the consensus markers identified by Jaillon et al., 2020 and Xue et al., 2022, we performed further clustering of the neutrophils in our dataset, resulting in the identification of three sub-types of TANs: pro-tumor TANs (Neu_03, marked with CD66, CD11, and MT1X), anti-tumor TANs (Neu_02, marked with CD66, CD11, CCL5, KRT5, and ELF3), TANs with isg (interferon-stimulated genes), and other undefined types (Neu_01, distinguished by CD66, CD11, IFITM2, S100A8, and LST1) (Figure 5B and C).